Quadriga Biosciences Reveals Positive Phase II Interim Data
03 Dec 2025 //
PR NEWSWIRE
Quadriga Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S
11 Apr 2023 //
PR NEWSWIRE
Quadriga concludes patient enrolment in Phase I solid tumour trial
26 Oct 2022 //
CLINICALTRIALSARENA

Market Place
Sourcing Support